niacinamide and Thyroid Neoplasms studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Research Excerpts

Excerpt	Relevance	Reference
" Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash."	9.17	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."	9.15	Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011)
"We measured serum thyroxine (T4), free T4, 3,5,3-triiodothyronine (T3), free T3, reverse T3 (rT3), and TSH concentrations at baseline and after 26 wk in 21 patients with progressive nonmedullary thyroid carcinoma treated with sorafenib."	9.14	Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. ( Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ, 2010)
" Sorafenib treatment was associated with Cushing's syndrome remission, elevated progesterone (>10 fold), normalization of dehydroepiandrostenedione sulfate, but persistently elevated cortisol concentration."	7.81	Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr ( Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW, 2015)
" Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma."	7.80	Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014)
" Here, we report a radioiodine-refractory follicular thyroid carcinoma (FTC) patient in whom a notable decrease of MPE was achieved after treatment with sorafenib."	7.80	Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. ( Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y, 2014)
" We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib."	7.79	Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013)
"Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer."	6.77	Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. ( Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW, 2012)
" However, adverse effects common to the tyrosine kinase inhibitor class occur at a noticeably higher rate with sorafenib use in thyroid cancer patients."	6.53	Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. ( Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016)
"Sorafenib was recently approved for the treatment of these patients."	5.42	Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."	5.38	Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. ( Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R, 2012)
"Everolimus was neither additive nor syngergistic in combination with sorafenib or AZD6244."	5.38	Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. ( Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C, 2012)
" Toxicity was manageable and as previously described for sorafenib, including hypertension and skin rash."	5.17	Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. ( Chapman, R; Dowlati, A; Fu, P; Lavertu, P; Nagaiah, G; Remick, SC; Savvides, P; Wasman, J; Wright, JJ, 2013)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."	5.15	Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. ( Chen, L; Lu, H; Luo, Q; Shen, Y; Yu, Y; Zhu, R, 2011)
"To evaluate the tolerability and efficacy of sorafenib in patients with thyroid carcinoma."	5.15	Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. ( Ahmed, M; Barbachano, Y; Harrington, KJ; Hickey, J; Marais, R; Newbold, KL; Nutting, CM; Riddell, A; Viros, A, 2011)
"We measured serum thyroxine (T4), free T4, 3,5,3-triiodothyronine (T3), free T3, reverse T3 (rT3), and TSH concentrations at baseline and after 26 wk in 21 patients with progressive nonmedullary thyroid carcinoma treated with sorafenib."	5.14	Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. ( Abdulrahman, RM; Corssmit, EP; Gelderblom, H; Hoftijzer, H; Hovens, GC; Kapiteijn, E; Pereira, AM; Reiners, C; Romijn, JA; Smit, JW; Verburg, E; Verloop, H; Visser, TJ, 2010)
" In endocrine tumors, several molecules have demonstrated efficacy in terms of progression free survival during phase III trials such as vandetanib and cabozantinib in medullary thyroid carcinoma, sorafenib in differentiated thyroid carcinoma and everolimus or sunitinib for pancreatic neuroendocrine tumors."	4.89	[Targeted therapies, prognostic and predictive factors in endocrine oncology]. ( Baudin, E; Borson-Chazot, F; Hescot, S; Lombès, M, 2013)
"Sorafenib is an oral multikinase inhibitor with regulatory approval in advanced renal cell carcinoma (RCC), hepatocellular carcinoma (HCC) and refractory differentiated thyroid carcinoma (DTC)."	4.12	Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. ( Imai, T; Kaneko, S; Okayama, Y; Oya, M; Sunaya, T; Tsujino, T, 2022)
"Sorafenib (BAY 43-9006) is an inhibitor of multiple-receptor tyrosine kinases involved in tumor growth and angiogenesis, which can be advantageously administered orally."	3.85	Sorafenib: rays of hope in thyroid cancer. ( Bernardini, R; Duntas, LH, 2010)
"Sorafenib, a multikinase inhibitor has recently been approved for the treatment of radio-iodine refractory thyroid carcinoma."	3.81	Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. ( Chen, G; Derwahl, M; Nicula, D; Renko, K, 2015)
" Sorafenib treatment was associated with Cushing's syndrome remission, elevated progesterone (>10 fold), normalization of dehydroepiandrostenedione sulfate, but persistently elevated cortisol concentration."	3.81	Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr ( Abouzied, Mel-D; Aklabi, S; Duaiji, N; Hammami, MM; Mutairi, G; Qattan, N; Sous, MW, 2015)
" Sorafenib is a small-molecule multikinase inhibitor used in radioactive iodine ((131)I)-refractive papillary thyroid carcinoma."	3.80	Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. ( Ewig, JM; Iyer, P; Mayer, JL, 2014)
"THERE WERE 62 PATIENTS (37 MEN, MEAN AGE: 61 years) treated with sorafenib (62%), sunitinib (22%), and vandetanib (16%) outside of clinical trials; 22 had papillary, five had follicular, five had Hürthle cell, 13 had poorly differentiated, and 17 had medullary thyroid carcinoma (MTC)."	3.80	Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. ( Baudin, E; Bonichon, F; Borget, I; Brassard, M; Chougnet, CN; Claude-Desroches, M; de la Fouchardière, C; Do Cao, C; Giraudet, AL; Leboulleux, S; Massicotte, MH; Schlumberger, M, 2014)
" Here, we report a radioiodine-refractory follicular thyroid carcinoma (FTC) patient in whom a notable decrease of MPE was achieved after treatment with sorafenib."	3.80	Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. ( Chen, L; Li, M; Liu, M; Ruan, M; Shen, Y, 2014)
" The relative role of such novel radiopharmaceutical versus (131)I scanning of thyroid cancer will require future histopathologic and clinical studies, but it may open new perspectives for presurgical staging of thyroid cancer, and diagnosis of radioiodine negative local relapses and/or distant metastases."	3.80	(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. ( Balogh, L; Dierckx, RA; Fremont, V; Galli, F; Manni, I; Piaggio, G; Signore, A; Szkudlinski, MW; Weintraub, BD, 2014)
"Before and after the last week of sorafenib therapy, 20 patients with progressive differentiated thyroid carcinoma received a standard dose regimen of two injections 0."	3.79	Sorafenib therapy decreases the clearance of thyrotropin. ( Dekkers, OM; Smit, JW; Verloop, H, 2013)
" We report a case of a 60-year-old woman who developed left renal artery stenosis associated with renal atrophy in the context of metastatic papillary thyroid carcinoma treated with sorafenib."	3.79	Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. ( Busaidy, NL; Habra, MA; Schellingerhout, D; Shawa, H, 2013)
"In a randomized phase III clinical trial, patients with metastatic differentiated cancer of the thyroid who were treated with sorafenib achieved median progression-free survival of 10."	3.79	Sorafenib makes headway on metastatic thyroid cancer. ( , 2013)
"Sorafenib is an oral multikinase inhibitor approved for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer (DTC)."	2.84	Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. ( Ito, KI; Ito, Y; Kabu, K; Onoda, N; Sugitani, I; Takahashi, S; Tsukada, K; Yamaguchi, I, 2017)
"One of 2 patients with anaplastic thyroid cancer had an objective response."	2.84	Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. ( Baxi, SS; Cullen, G; Dunn, LA; Fagin, JA; Fury, MG; Ghossein, RA; Haque, S; Ho, AL; Pfister, DG; Sherman, EJ; Sima, CS, 2017)
"Effective adverse event (AE) management is critical to maintaining patients on anticancer therapies."	2.80	Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. ( Ando, Y; Bonichon, F; Brose, MS; Chung, J; Fassnacht, M; Fugazzola, L; Gao, M; Hadjieva, T; Hasegawa, Y; Kappeler, C; Meinhardt, G; Park, DJ; Schlumberger, M; Shi, Y; Shong, YK; Smit, JW; Worden, F, 2015)
"Patients with advanced thyroid cancer derived meaningful clinical benefit from additional therapy with a biologic agent following disease progression on front-line targeted therapy."	2.78	Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. ( Chen, Z; Chowdry, RP; Khuri, FR; Kim, S; Owonikoko, TK; Saba, NF; Shin, DM, 2013)
"Sorafenib has clinically relevant antitumor activity in patients with progressive metastatic or locally advanced radio-iodine refractory differentiated thyroid cancer."	2.77	Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. ( Abdulrahman, RM; Corssmit, EP; Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JW, 2012)
"Sorafenib is a multikinase inhibitor that targets several molecular signals believed to be involved in the pathogenesis of thyroid cancer, including those implicated in DTC."	2.76	Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca ( Brose, MS; Chung, J; Kalmus, J; Kappeler, C; Nutting, CM; Reike, G; Schlumberger, M; Sherman, SI; Shong, YK; Smit, JW, 2011)
" The most common treatment-related adverse events were diarrhea (41%), fatigue (41%), hypothyroidism (29%), hypertension (27%), and anorexia (27%)."	2.74	Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. ( Bastholt, L; Daumerie, C; Droz, JP; Elisei, R; Eschenberg, MJ; Jarzab, B; Juan, T; Locati, LD; Martins, RG; Pacini, F; Schlumberger, MJ; Sherman, SI; Stepan, DE; Sun, YN; Wirth, LJ, 2009)
"Sorafenib has a beneficial effect on tumor progression in patients with metastatic DTC, but was less effective in patients with bone metastases."	2.74	Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. ( Corssmit, EP; Gelderblom, H; Heemstra, KA; Hoftijzer, H; Huijberts, M; Kapiteijn, E; Morreau, H; Pereira, AM; Romijn, JA; Smit, JW; Stokkel, MP; Weijers, K, 2009)
"Sorafenib has clinically relevant antitumor activity in patients with metastatic, iodine-refractory thyroid carcinoma, with an overall clinical benefit rate (partial response + stable disease) of 77%, median PFS of 79 weeks, and an overall acceptable safety profile."	2.73	Phase II trial of sorafenib in advanced thyroid cancer. ( Brose, MS; Flaherty, KT; Gupta-Abramson, V; Loevner, LA; Mandel, SJ; Nellore, A; O'Dwyer, PJ; Puttaswamy, K; Ransone, K; Redlinger, M; Troxel, AB, 2008)
"Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both antiproliferative and antiangiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumoral cells (c-RAF [proto-oncogene serine/threonine-protein kinase], BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3) and in tumor vessels (c-RAF, vascular endothelial growth factor receptor [VEGFR]-2, VEGFR-3, and platelet-derived growth factor receptor β)."	2.55	Aggressive thyroid cancer: targeted therapy with sorafenib. ( Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Mazzi, V; Miccoli, M; Miccoli, P; Politti, U; Ulisse, S, 2017)
"Distant metastases from differentiated thyroid cancer (DTC) are a rare event, occurring in less than 10% of patients with persistent or recurrent clinical disease."	2.55	Which patient with thyroid cancer deserves systemic therapy and when? ( Pacini, F, 2017)
" However, adverse effects common to the tyrosine kinase inhibitor class occur at a noticeably higher rate with sorafenib use in thyroid cancer patients."	2.53	Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. ( Jaffry, A; Jean, GW; Khan, SA; Mani, RM, 2016)
"Treatment of differentiated thyroid cancer consists of surgery followed by radioactive iodine (RAI) ablation of the thyroid remnant, and TSH suppression."	2.53	Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. ( Brzostek, T; Kawalec, P; Kózka, M; Malinowska-Lipień, I, 2016)
"Sorafenib is a multiple kinase inhibitor (MKI) approved for the treatment of primary advanced renal cell carcinoma and advanced primary liver cancer."	2.53	Selective use of sorafenib in the treatment of thyroid cancer. ( Jerkovich, F; Pitoia, F, 2016)
"Differentiated thyroid cancer is the most common endocrine malignancy, and its incidence has been rising rapidly over the past 10 years."	2.52	Targeted therapies in advanced differentiated thyroid cancer. ( Agulnik, M; Carneiro, BA; Carneiro, RM; Giles, FJ; Kopp, PA, 2015)
"Sorafenib is an oral multikinase inhibitor with anticancer activity against a wide spectrum of cancers."	2.52	Sorafenib: 10 years after the first pivotal trial. ( Abbate, I; Brandi, M; De Rose, F; Divella, R; Ferraro, E; Filippelli, G; Gadaleta-Caldarola, G; Infusino, S; Mazzocca, A, 2015)
"Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic chemotherapy."	2.52	Treatment of advanced thyroid cancer: role of molecularly targeted therapies. ( Covell, LL; Ganti, AK, 2015)
"Sorafenib (Nexavar) is an oral multi-kinase inhibitor targeting B-type Raf kinase (BRAF) (both wild type and BRAF(V600E)), VEGFR1, VEGFR2, VEGFR3, PDGFRβ and RET (also RET/PTC) influencing both differentiated thyroid cancer (DTC) cell proliferation and angiogenesis."	2.52	Sorafenib for the treatment of thyroid cancer: an updated review. ( Handkiewicz-Junak, D; Jarzab, B; Krajewska, J, 2015)
"The treatment of differentiated thyroid cancer refractory to radioactive iodine (RAI) had been hampered by few effective therapies."	2.52	Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. ( Colevas, AD; Gruber, JJ, 2015)
"Sorafenib was specifically developed to target rapidly accelerated fibrosarcoma (RAF) kinase in the MAPK pathway."	2.52	The discovery and development of sorafenib for the treatment of thyroid cancer. ( Cohen, MS; White, PT, 2015)
"Radio-iodine refractory metastatic thyroid cancers are rare and their management was until recently relatively complex."	2.52	Targeted treatments of radio-iodine refractory differentiated thyroid cancer. ( de la Fouchardière, C, 2015)
"Treatment with sorafenib in patients with progressive DTC and MTC is a promising strategy, but the adverse event rate is high, leading to a high rate of dose reduction or discontinuation."	2.50	Sorafenib in metastatic thyroid cancer: a systematic review. ( Cabanillas, ME; Dadu, R; Dong, W; Feng, L; Lai, SY; Regone, RM; Thomas, L, 2014)
"Sorafenib (Nexavar) is a multikinase inhibitor, which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumor cell [c-RAF (proto-oncogene serine/threonine-protein kinase), BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3] and in tumor vessels (c-RAF, vascular endothelial growth factor receptor-2, vascular endothelial growth factor receptor-3, and platelet-derived growth factor receptor β)."	2.49	Sorafenib and thyroid cancer. ( Antonelli, A; Corrado, A; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Santini, F; Ulisse, S, 2013)
"The incidence of thyroid cancer continues to increase and this neoplasia remains the most common endocrine malignancy."	2.48	Novel molecular targeted therapies for refractory thyroid cancer. ( Arango, BA; Cohen, EE; Perez, CA; Raez, LE; Santos, ES, 2012)
"The prognosis of almost all thyroid cancers is good, but some patients have indications for these molecularly targeted drugs."	2.47	Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. ( Takami, HE, 2011)
"Medullary thyroid carcinoma has a worse prognosis, especially in patients with diffused cancers at the time of initial surgery."	2.45	Targeted molecular therapies in thyroid carcinoma. ( Moretti, S; Puxeddu, E; Romagnoli, S; Voce, P, 2009)
"PTC represents 80-90% of all thyroid cancers and over the past five years, more than 200 manuscripts have been published about the relationship between "B-Raf(V600E) and thyroid cancer"."	2.45	Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). ( Goldfarb, M; Hodin, R; Nucera, C; Parangi, S, 2009)
"Treatment of patients with thyroid cancer is usually successful, and most patients are cured of the disease."	2.42	How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. ( Fagin, JA, 2004)
"Chloroquine (CQ) is an autophagy inhibitor that has been reported to increase sensitivity to various cancer treatments."	1.48	Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer. ( Ge, M; Jin, S; Li, L; Long, B; Yang, M; Ye, T; Ye, X; Yi, H; Zhang, L, 2018)
"Treatment with sorafenib was initiated, resulting in significant tumor reduction allowing near total thyroidectomy and bilateral neck dissection."	1.48	Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. ( Bonani, FA; Camargo, RY; Castro, G; Coura-Filho, GB; Danilovic, DLS; Freitas, RMC; Hoff, AO; Kulcsar, MA; Marui, S; Roitberg, FSR; Vanderlei, FAB, 2018)
" Additional secondary endpoints are postprogression survival from time of symptomatic progression, duration of and response to each systemic treatment regimen and dosing of sorafenib throughout the treatment period."	1.46	Timing of multikinase inhibitor initiation in differentiated thyroid cancer. ( Brose, MS; DeSanctis, Y; Fellous, M; Lin, CC; Pitoia, F; Schlumberger, M; Smit, J; Sugitani, I; Tori, M, 2017)
"Sorafenib is a multikinase inhibitor of RTKs and the MAPK pathway and has recently been used for the treatment of unresectable well-differentiated thyroid carcinoma."	1.46	Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. ( Chiba, T; Hara, H; Ishii, J; Kamma, H; Sawa, A; Yamamoto, H, 2017)
"Anaplastic thyroid cancer (ATC) comprises approximately 2% of all thyroid cancers, and its median survival rate remains poor."	1.43	Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). ( Abdulghani, J; Cooper, T; Derr, J; Dicker, D; El-Deiry, WS; Finnberg, NK; Gallant, JN; Gokare, P; Goldenberg, D; Liao, J; Liu, J; Whitcomb, T, 2016)
"Lenvatinib is an oral potent multi kinase inhibitor [MKI] of different growth factor receptors including VEGFR1/Flt-1, VEGFR2/KDR, VEGFR3, FGFR1,2,3,4, PDGFR-β as well as RET and KIT signaling networks."	1.43	Efficacy of lenvatinib in treating thyroid cancer. ( Jarzab, B; Krajewska, J; Kukulska, A, 2016)
"Sorafenib treatment could be considered when vandetanib and cabozantinib are not available or after failing these drugs."	1.43	Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. ( de Castro, G; de Castroneves, LA; de Freitas, RM; Fukushima, JT; Hoff, AO; Hoff, PM; Jorge, AA; Kulcsar, MA; Lima, JV; Negrão, MV; Papadia, C; Simão, EF; Tavares, MR, 2016)
"Differentiated thyroid cancers are usually cured by an appropriate surgery and a radioiodine remnant ablation."	1.43	[Lenvatinib in radioiodine refractory thyroid carcinomas]. ( de la Fouchardiere, C, 2016)
" In BRAF-mutant melanomas, orally bioavailable B-Raf inhibitors, such as vemurafenib, achieve dramatic responses initially, but this is followed by rapid emergence of resistance driven by numerous mechanisms and requiring second-generation treatment approaches."	1.43	B-Raf Inhibition in the Clinic: Present and Future. ( Fiskus, W; Mitsiades, N, 2016)
"The curcumin was found to dose-dependently inhibit the apoptosis of FTC133 cells possibly via PI3K/Akt and ERK pathways."	1.43	Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways. ( Chen, W; Lv, Y; Xie, R; Yu, J; Zhang, J, 2016)
"Sorafenib has an antitumor activity in patients with radioactive iodine-refractory differentiated thyroid carcinoma (RAIR-DTC)."	1.43	pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. ( Brose, MS; Chen, EY; Cohen, AB; Feldman, MD; Johnson, BA; Ma, C; Pappas-Paxinos, M; Stopenski, SJ; Tang, W; Troxel, AB; Yarchoan, M, 2016)
"Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors."	1.43	(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. ( Kapiteijn, E; Morreau, H; Schneider, TC; Smit, JWA; van der Hoeven, JJM; van Wezel, T, 2016)
"Sorafenib was recently approved for the treatment of these patients."	1.42	Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. ( Abelleira, E; Cross, G; Jerkovich, F; Pitoia, F; Urciuoli, C, 2015)
"Pretreatment with sorafenib also inhibited PBMC expression of IFN-α- and IL-2-regulated genes and inhibited NK cell production of IFN-γ, RANTES, MIP1-α, and MIG in response to IFN-α stimulation."	1.42	The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. ( Byrd, JC; Caligiuri, MA; Campbell, AR; Carson, WE; Fairchild, ET; Grignol, VP; Guenterberg, KD; Jaime-Ramirez, AC; Karpa, VI; Kondadasula, SV; Lesinski, GB; Levine, KM; Mace, TA; Markowitz, J; Martin del Campo, SE; McClory, S; Monk, JP; Mortazavi, A; Mundy-Bosse, BL; Olencki, TE; Pan, X; Paul, BK; Shah, MH; Tridandapani, S; Trikha, P, 2015)
"Sorafenib treatment caused a rapid inhibition of various MAP kinases in addition to inhibiting AKT and receptor tyrosine kinases."	1.42	Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. ( Britten, M; Broecker-Preuss, M; Fuhrer, D; Mann, K; Müller, S; Schmid, KW; Worm, K, 2015)
"Sorafenib has been evaluated in several Phase II and III studies in patients with locally advanced/metastatic radioactive iodine-refractory differentiated thyroid carcinomas (DTCs), reporting partial responses, stabilization of the disease and improvement of progression-free survival."	1.42	Sorafenib in the treatment of thyroid cancer. ( Antonelli, A; Baldini, E; Fallahi, P; Ferrari, SM; Materazzi, G; Miccoli, P; Politti, U; Spisni, R; Ulisse, S, 2015)
"Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine."	1.40	Thyroid carcinoma, version 2.2014. ( Ball, DW; Byrd, D; Dickson, P; Duh, QY; Ehya, H; Haddad, RI; Haymart, M; Hoffmann, KG; Hoh, C; Hughes, M; Hunt, JP; Iagaru, A; Kandeel, F; Kopp, P; Lamonica, DM; Lydiatt, WM; McCaffrey, J; Moley, JF; Parks, L; Raeburn, CD; Ridge, JA; Ringel, MD; Scheri, RP; Shah, JP; Sherman, SI; Sturgeon, C; Tuttle, RM; Waguespack, SG; Wang, TN; Wirth, LJ, 2014)
"Treatment with sorafenib 400 mg twice a day was initiated resulting in a rapid and significant reduction of cortisol and ACTH levels associated with dramatic clinical improvement."	1.40	Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome. ( Barroso-Sousa, R; Evangelista, J; Fragoso, MC; Hoff, AO; Kulcsar, MA; Lerario, AM; Lin, CS; Lourenço, DM; Papadia, C, 2014)
"Sorafenib doses were increased up to 1600 mg bid, in order to maintain clinical activity, and to restore active plasma concentration, since sorafenib exposure had decreased over the time."	1.40	Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. ( Bellesoeur, A; Billemont, B; Blanchet, B; Carton, E; Clerc, J; Goldwasser, F; Groussin, L; Mir, O, 2014)
"Sorafenib has recently been recognized as an important standard option for the management of patients with differentiated thyroid cancer."	1.40	Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis. ( Giusti, M; Minuto, F; Monti, E; Morbelli, S; Mortara, L; Pera, G; Sambuceti, G, 2014)
"Sorafenib has proven efficacy in advanced differentiated thyroid cancer (DTC), but many patients must reduce the dose or discontinue treatment because of toxicity."	1.40	Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. ( Bassett, RL; Busaidy, NL; Cabanillas, ME; Dadu, R; Habra, MA; Hu, MI; Jimenez, C; Sherman, SI; Waguespack, SG; Ying, AK, 2014)
"Thyroid cancer is the most prevalent endocrine malignancy."	1.40	To treat or not to treat: developments in the field of advanced differentiated thyroid cancer. ( Corssmit, EP; Kapiteijn, E; Links, TP; Oosting, SF; Schneider, TC; van der Horst-Schrivers, AN, 2014)
"Sorafenib was mostly well tolerated, but a high incidence of fatal events was reported (three patients died from severe bleeding events and two from cardiac arrest)."	1.39	Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. ( Camera, L; Colao, A; Del Prete, M; Esposito, R; Faggiano, A; Fonti, R; Marotta, V; Palmieri, G; Ramundo, V; Salvatore, M; Vitale, M, 2013)
"Medullary thyroid cancer (MTC) is frequently associated with mutations in the tyrosine kinase Ret and with increased expression of vascular endothelial growth factor (VEGF) and VEGF receptor 2 (VEGFR2)."	1.38	Anti-tumor activity of motesanib in a medullary thyroid cancer model. ( Bready, J; Canon, J; Coxon, A; Estrada, J; Hughes, P; Kaufman, S; Kendall, R; Osgood, T; Polverino, A; Radinsky, R; Wang, L, 2012)
"Everolimus was neither additive nor syngergistic in combination with sorafenib or AZD6244."	1.38	Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. ( Agarwal, K; Brendel, VJ; Jarjoura, D; Koh, YW; Koo, BS; McCarty, SK; Porter, K; Ringel, MD; Saji, M; Shah, MH; Wang, C, 2012)
"Although thyroid cancer usually has an excellent prognosis, few therapeutic options are available in the refractory setting."	1.38	Sorafenib in metastatic thyroid cancer. ( Capdevila, J; Corral, J; Grande, E; Grau, JJ; Halperin, I; Iglesias, L; Martínez-Trufero, J; Obiols, G; Segura, A; Tabernero, J; Vaz, MÁ, 2012)
"Here we present a man with pancreatic metastases from PTC, report our experience with sorafenib therapy, and discuss the role of endoscopic ultrasound (EUS)-guided biopsy in its diagnosis."	1.38	Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. ( Abalkhail, H; Al Sohaibani, F; Almanea, H; AlQaraawi, A; Alzahrani, AS, 2012)
"Sorafenib has shown promise in the treatment of patients with advanced or metastatic thyroid carcinoma."	1.38	Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. ( Chen, L; Lu, H; Luo, Q; Ruan, M; Shen, Y; Yu, Y; Zhu, R, 2012)
"Medullary thyroid cancer-1."	1.38	Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. ( Lin, CI; Lorch, JH; Ruan, DT; Whang, EE, 2012)
" The mice were randomized into seven groups: blank control (A), vehicle control (B), single liposome doxorubicin (C), single sorafenib group (D), liposome doxorubicin combined with low dose sorafenib group (E), combined group with medium dosage of sorafenib (F), combined group with high-dose of sorafenib(G)."	1.38	[Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice]. ( An, CM; Han, ZK; Li, ZJ; Ma, J; Tang, PZ; Wang, Z, 2012)
"Patients with progressive refractory thyroid cancer are potential candidates for clinical trials using tyrosine kinase inhibitors (TKIs), and a promising proportion of patients in these trials have achieved stable disease."	1.37	Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. ( Bousquet, G; Faugeron, I; Hindie, E; Lussato, D; Toubert, ME; Vercellino, L, 2011)
" 3 patients remain on sorafenib, 2 at a reduced dosage (600 mg/d)."	1.37	Rapid response to sorafenib in metastatic medullary thyroid carcinoma. ( Frank-Raue, K; Ganten, M; Kreissl, MC; Raue, F, 2011)
"Sorafenib is a multikinase inhibitor that blocks tumor cell proliferation and angiogenesis and is used for the treatment of advanced renal cell carcinoma, unresectable hepatocellular carcinoma, and other solid tumors."	1.36	Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. ( Chon, SY; Diamantis, ML, 2010)
"Sorafenib was used in 13 and sunitinib in two, including one patient who failed prior sorafenib therapy."	1.36	Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. ( Bronstein, Y; Busaidy, NL; Cabanillas, ME; Feng, L; Hernandez, M; Lopez, A; Sherman, SI; Waguespack, SG; Williams, MD, 2010)
" Dose-response simulations were performed in patients with differentiated thyroid cancer."	1.36	Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. ( Bruno, R; Claret, L; Lu, JF; Sun, YN, 2010)
" Motesanib concentrations were fitted to a 2-compartment population pharmacokinetic model."	1.36	Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. ( Bruno, R; Claret, L; Kuchimanchi, M; Lu, JF; Melara, R; Sun, YN; Sutjandra, L, 2010)
"Sorafenib is an orally administered multi-kinase inhibitor that has shown promise in the treatment of adults with advanced thyroid cancer, but it has not yet been studied in children with this disease."	1.35	The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. ( Clayman, GL; Herzog, CE; Sherman, SI; Waguespack, SG; Williams, MD, 2009)
"Suppression of BRAF pathway in thyroid cancer cell lines (8505C, TPC1 and C643) was achieved using RNA interference (RNAi) for BRAF and the kinase inhibitor, sorafenib."	1.35	Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. ( Figueiredo, J; Gonçalves, J; Meireles, AM; Preto, A; Rebocho, AP; Rocha, AS; Seca, H; Seruca, R; Soares, P; Sobrinho-Simões, M; Vasconcelos, HM, 2009)
"Differentiated thyroid cancer and hyperthyroidism are treated with radioiodine."	1.33	Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides. ( Agote Robertson, M; Dagrosa, MA; Finochietto, P; Franco, MC; Gamba, CA; Juvenal, GJ; Pisarev, MA; Poderoso, JJ; Viaggi, ME, 2006)

Research

Studies (165)

Authors

Clinical Trials (14)

Trial Overview

Trial Outcomes

AUC(0-12h),ss (Area Under the Concentration Time Curve From Time 0 to 12 Hours at Steady State)

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (0.61)	18.7374
1990's	0 (0.00)	18.2507
2000's	22 (13.33)	29.6817
2010's	138 (83.64)	24.3611
2020's	4 (2.42)	2.80

Authors	Studies
Farias, EC	1
Hoff, AO	4
Oya, M	1
Kaneko, S	1
Imai, T	1
Tsujino, T	1
Sunaya, T	1
Okayama, Y	1
Celano, M	1
Maggisano, V	1
Bulotta, S	1
Allegri, L	1
Pecce, V	1
Abballe, L	1
Damante, G	1
Russo, D	1
Tang, K	1
Wang, Z	2
Lin, J	1
Zheng, X	1
Wilson, L	1
Huang, W	1
Chen, L	5
Ting, J	1
Cao, V	1
Yi, H	2
Ye, X	3
Long, B	2
Ye, T	2
Zhang, L	2
Yan, F	1
Yang, Y	1
Li, L	2
Ito, Y	1
Onoda, N	1
Ito, KI	1
Sugitani, I	2
Takahashi, S	1
Yamaguchi, I	1
Kabu, K	1
Tsukada, K	1
Sherman, EJ	1
Dunn, LA	1
Ho, AL	1
Baxi, SS	1
Ghossein, RA	1
Fury, MG	1
Haque, S	1
Sima, CS	1
Cullen, G	1
Fagin, JA	3
Pfister, DG	2
Sawa, A	1
Chiba, T	1
Ishii, J	1
Yamamoto, H	1
Hara, H	1
Kamma, H	1
Pacini, F	3
Matrone, A	1
Valerio, L	1
Pieruzzi, L	1
Giani, C	1
Cappagli, V	1
Lorusso, L	1
Agate, L	1
Puleo, L	1
Viola, D	1
Bottici, V	1
Del Re, M	1
Molinaro, E	1
Danesi, R	1
Elisei, R	3
Felicetti, F	2
Nervo, A	2
Piovesan, A	2
Berardelli, R	1
Marchisio, F	1
Gallo, M	2
Arvat, E	2
Ge, M	1
Yang, M	1
Jin, S	1
Molina-Vega, M	1
García-Alemán, J	1
Sebastián-Ochoa, A	1
Mancha-Doblas, I	1
Trigo-Pérez, JM	1
Tinahones-Madueño, F	1
Danilovic, DLS	1
Castro, G	1
Roitberg, FSR	1
Vanderlei, FAB	1
Bonani, FA	1
Freitas, RMC	1
Coura-Filho, GB	1
Camargo, RY	1
Kulcsar, MA	3
Marui, S	1
Iyer, P	1
Mayer, JL	1
Ewig, JM	1
Martínez-Rodríguez, I	1
Banzo, I	1
Carril, JM	1
Kurzrock, R	3
Atkins, J	1
Wheler, J	2
Fu, S	1
Naing, A	2
Busaidy, N	1
Hong, D	2
Sherman, S	1
Shawa, H	1
Busaidy, NL	5
Schellingerhout, D	1
Habra, MA	3
Eisner, F	1
Schaberl-Moser, R	1
Gerger, A	1
Samonigg, H	1
Pichler, M	1
Fallahi, P	3
Ferrari, SM	3
Santini, F	1
Corrado, A	2
Materazzi, G	3
Ulisse, S	3
Miccoli, P	3
Antonelli, A	3
Wunderlich, A	1
Khoruzhyk, M	1
Roth, S	1
Ramaswamy, A	1
Greene, BH	1
Doll, D	1
Bartsch, DK	1
Hoffmann, S	1
Owonikoko, TK	1
Chowdry, RP	1
Chen, Z	1
Kim, S	3
Saba, NF	1
Shin, DM	1
Khuri, FR	1
Shen, CT	2
Qiu, ZL	2
Luo, QY	2
Hescot, S	1
Baudin, E	2
Borson-Chazot, F	1
Lombès, M	1
Bellesoeur, A	2
Carton, E	1
Mir, O	2
Groussin, L	1
Blanchet, B	3
Billemont, B	1
Clerc, J	2
Goldwasser, F	5
Massicotte, MH	1
Brassard, M	1
Claude-Desroches, M	1
Borget, I	1
Bonichon, F	2
Giraudet, AL	1
Do Cao, C	1
Chougnet, CN	1
Leboulleux, S	1
Schlumberger, M	5
de la Fouchardière, C	4
Barroso-Sousa, R	1
Lerario, AM	1
Evangelista, J	1
Papadia, C	2
Lourenço, DM	1
Lin, CS	1
Fragoso, MC	1
Thomas, L	1
Lai, SY	2
Dong, W	1
Feng, L	2
Dadu, R	4
Regone, RM	1
Cabanillas, ME	6
Devine, C	1
Hernandez, M	3
Waguespack, SG	6
Hu, MI	2
Jimenez, C	2
Sellin, RV	1
Ying, AK	2
Cote, GJ	1
Sherman, SI	13
Liu, M	2
Shen, Y	3
Ruan, M	3
Li, M	1
Pitoia, F	4
Bassett, RL	1
Haraldsdottir, S	1
Shah, MH	6
Brose, MS	8
Nutting, CM	3
Jarzab, B	4
Siena, S	2
Bastholt, L	3
Paschke, R	1
Shong, YK	3
Smit, JW	7
Chung, J	3
Kappeler, C	4
Peña, C	2
Molnár, I	1
Schlumberger, MJ	5
Galli, F	1
Manni, I	1
Piaggio, G	1
Balogh, L	1
Weintraub, BD	1
Szkudlinski, MW	1
Fremont, V	1
Dierckx, RA	1
Signore, A	1
Takami, H	1
Ito, K	1
Sugino, K	1
Huillard, O	2
Boudou-Rouquette, P	2
Thomas-Schoemann, A	2
Wassermann, J	1
Marotta, V	4
Sciammarella, C	2
Vitale, M	2
Colao, A	4
Faggiano, A	4
Mortara, L	1
Pera, G	1
Monti, E	1
Morbelli, S	1
Minuto, F	1
Sambuceti, G	1
Giusti, M	1
Di Somma, C	1
Rubino, M	1
Modica, R	1
Camera, L	2
Del Prete, M	2
Marciello, F	1
Ramundo, V	2
Circelli, L	1
Buonomano, P	1
Schneider, TC	3
Kapiteijn, E	5
Corssmit, EP	4
Oosting, SF	1
van der Horst-Schrivers, AN	1
Links, TP	1
Michelon, F	1
Castiglione, A	1
Viansone, AA	1
Zichi, C	1
Ciccone, G	1
Lindner, C	1
Dierneder, J	1
Pall, G	1
Pirich, C	1
Hoffmann, M	1
Raderer, M	1
Becherer, A	1
Niederle, B	1
Lipp, R	1
Lind, P	1
Gallowitsch, H	1
Romeder, F	1
Virgolini, I	1
Tuttle, RM	2
Haddad, RI	1
Ball, DW	1
Byrd, D	1
Dickson, P	1
Duh, QY	1
Ehya, H	1
Haymart, M	1
Hoh, C	1
Hunt, JP	1
Iagaru, A	1
Kandeel, F	1
Kopp, P	1
Lamonica, DM	1
Lydiatt, WM	1
McCaffrey, J	1
Moley, JF	2
Parks, L	1
Raeburn, CD	1
Ridge, JA	1
Ringel, MD	4
Scheri, RP	1
Shah, JP	1
Sturgeon, C	1
Wang, TN	1
Wirth, LJ	4
Hoffmann, KG	1
Hughes, M	1
Krajewska, J	2
Handkiewicz-Junak, D	1
Gruber, JJ	1
Colevas, AD	1
Mato, E	1
Barceló-Batllori, S	1
Orera, I	1
Selva, L	1
Corra, M	1
González, C	1
Bell, O	1
Lerma, E	1
Moral, A	1
Pérez, JI	1
de Leiva, A	1
White, PT	1
Cohen, MS	2
Chen, G	1
Nicula, D	1
Renko, K	1
Derwahl, M	1
Durand, JP	1
Lee, HJ	1
Ryu, H	1
Choi, YS	1
Song, IC	1
Yun, HJ	1
Jo, DY	1
Blair, HA	1
Plosker, GL	1
Dong, Q	1
Broecker-Preuss, M	1
Müller, S	1
Britten, M	1
Worm, K	1
Schmid, KW	1
Mann, K	1
Fuhrer, D	1
Wang, E	1
Karedan, T	1
Perez, CA	2
Moreo, A	1
Vallerio, P	1
Ricotta, R	1
Stucchi, M	1
Pozzi, M	1
Musca, F	1
Meani, P	1
Maloberti, A	1
Facchetti, R	1
Di Bella, S	1
Giganti, MO	1
Sartore-Bianchi, A	1
Mancia, G	1
Giannattasio, C	1
Carneiro, RM	1
Carneiro, BA	1
Agulnik, M	1
Kopp, PA	1
Giles, FJ	1
Politti, U	2
Mazzi, V	1
Miccoli, M	1
Spisni, R	1
Baldini, E	1
Gadaleta-Caldarola, G	1
Infusino, S	1
Divella, R	1
Ferraro, E	1
Mazzocca, A	1
De Rose, F	1
Filippelli, G	1
Abbate, I	1
Brandi, M	1
Martin del Campo, SE	1
Levine, KM	1
Mundy-Bosse, BL	1
Grignol, VP	1
Fairchild, ET	1
Campbell, AR	1
Trikha, P	1
Mace, TA	1
Paul, BK	1
Jaime-Ramirez, AC	1
Markowitz, J	1
Kondadasula, SV	1
Guenterberg, KD	1
McClory, S	1
Karpa, VI	1
Pan, X	1
Olencki, TE	1
Monk, JP	1
Mortazavi, A	1
Tridandapani, S	1
Lesinski, GB	1
Byrd, JC	1
Caligiuri, MA	1
Carson, WE	1
Kiyota, N	1
Zhang, J	1
Yu, J	1
Xie, R	1
Chen, W	1
Lv, Y	1
Abelleira, E	1
Jerkovich, F	2
Urciuoli, C	1
Cross, G	1
Covell, LL	1
Ganti, AK	1
Hammami, MM	1
Duaiji, N	1
Mutairi, G	1
Aklabi, S	1
Qattan, N	1
Abouzied, Mel-D	1
Sous, MW	1
Worden, F	1
Fassnacht, M	2
Shi, Y	1
Hadjieva, T	1
Gao, M	1
Fugazzola, L	1
Ando, Y	1
Hasegawa, Y	1
Park, DJ	1
Meinhardt, G	1
Zhu, Y	1
Cai, J	1
Dunna, NR	1
Kandula, V	1
Girdhar, A	1
Pudutha, A	1
Hussain, T	1
Bandaru, S	1
Nayarisseri, A	1
de Castroneves, LA	1
Negrão, MV	1
de Freitas, RM	1
Lima, JV	1
Fukushima, JT	1
Simão, EF	1
Tavares, MR	1
Jorge, AA	1
de Castro, G	1
Hoff, PM	1
Fiskus, W	1
Mitsiades, N	1
van Wezel, T	1
Smit, JWA	1
van der Hoeven, JJM	1
Morreau, H	3
Jean, GW	1
Mani, RM	1
Jaffry, A	1
Khan, SA	1
Okano, S	1
Yarchoan, M	1
Ma, C	1
Troxel, AB	2
Stopenski, SJ	1
Tang, W	1
Cohen, AB	1
Pappas-Paxinos, M	1
Johnson, BA	1
Chen, EY	1
Feldman, MD	1
Mirantes, C	1
Dosil, MA	1
Eritja, N	1
Felip, I	1
Gatius, S	1
Santacana, M	1
Matias-Guiu, X	1
Dolcet, X	1
Abdulghani, J	1
Gokare, P	1
Gallant, JN	1
Dicker, D	1
Whitcomb, T	1
Cooper, T	1
Liao, J	1
Derr, J	1
Liu, J	1
Goldenberg, D	1
Finnberg, NK	1
El-Deiry, WS	1
Kukulska, A	1
Basu, S	1
Joshi, A	1
Kawalec, P	1
Malinowska-Lipień, I	1
Brzostek, T	1
Kózka, M	1
Dang, RP	1
McFarland, D	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
A Phase 1 Dose-Escalation Study of the Safety and Pharmacokinetics of XL184 Administered Orally to Subjects With Advanced Malignancies[NCT00215605]	Phase 1	85 participants (Actual)	Interventional	2005-09-30	Completed
Phase I Study of Tipifarnib (R115777) and Sorafenib (BAY 43-9006) in Patients With Biopsiable Advanced Cancers[NCT00244972]	Phase 1	74 participants (Actual)	Interventional	2005-10-31	Completed
A Phase I/Ib, Multicenter, Open-Label, Dose Escalation Study of E7080 in Patients With Solid Tumors and in Combination With Temozolomide in Patients With Advanced and/or Metastatic Melanoma[NCT00121680]	Phase 1	115 participants (Actual)	Interventional	2005-07-31	Completed
A Multi-Arm Complete Phase 1 Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor[NCT00495872]	Phase 1	204 participants (Actual)	Interventional	2007-06-30	Completed
Vessels Encapsulating Tumor Clusters (VETC), Prognostic and Predictive Value in Renal Cell Carcinoma and Adrenal Gland Carcinoma[NCT04666220]		180 participants (Anticipated)	Observational	2021-01-02	Recruiting
A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer[NCT00984282]	Phase 3	417 participants (Actual)	Interventional	2009-10-15	Completed
RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors[NCT02303444]		667 participants (Actual)	Observational	2015-04-08	Completed
Impact of BRAFV600E Intratumor Heterogeneity on the Efficacy of Tyrosine Kinase Inhibitors in the Treatment of Radioiodine-resistant Thyroid Cancer[NCT01700699]		50 participants (Anticipated)	Observational	2012-10-31	Recruiting
A Randomized, Multicenter, Open-label, Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma[NCT01813136]	Phase 2	168 participants (Actual)	Interventional	2013-03-31	Completed
A Phase 2, Open-label Study of AMG 706 to Treat Subjects With Locally Advanced or Metastatic Thyroid Cancer[NCT00121628]	Phase 2	184 participants (Actual)	Interventional	2005-07-31	Completed
Personalized Cancer Therapy for Patients With Metastatic Medullary Thyroid or Metastatic Colon Cancer[NCT02363647]		10 participants (Actual)	Interventional	2015-01-31	Terminated (stopped due to No Current Funding)
Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma[NCT00887107]	Phase 2	32 participants (Actual)	Interventional	2007-10-31	Completed
Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials[NCT06079723]		500 participants (Anticipated)	Observational	2024-11-30	Not yet recruiting
Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid[NCT00126568]	Phase 2	20 participants (Actual)	Interventional	2005-06-30	Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Sorafenib AUC(0-12h),ss (area under the concentration time curve from time 0 to 12 hours at steady state) was estimated from the steady state plasma concentration. (NCT00984282)
Timeframe: A single pharmacokinetic plasma sample was collected at steady state (after 14 days of uninterrupted, unmodified sorafenib dosing)

Disease Control Rate (DCR) Based on Central Assessment

Intervention	mg*h/L (Geometric Mean)
Sorafenib (Nexavar, BAY43-9006)	75.4

Disease control rate was defined as the proportion of subjects whose best response was complete response (CR), partial response (PR), or stable disease (SD). Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria, CR and PR were to be confirmed by another scan at least 4 weeks later; SD had to be documented at least 4 weeks after date of randomization. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. SD = steady state of disease which is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Duration of Response (DOR) Based on Central Assessment

Intervention	Percentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006)	86.2
Placebo	74.6

Duration of response was defined as the time from the first documented objective response of PR or CR, whichever was noted earlier, to disease progression or death (if death occurred before progression was documented). CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Overall Survival (OS)

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	309
Placebo	NA

Overall survival was defined as the time (days) from date of randomization to date of death due to any cause. Subjects still alive at the time of analysis were censored at their date of last contact. Since the median value could not be estimated due to censored data, the percentage of participants who died is presented. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (30 AUG 2017), study duration approximately eight years

Progression-free Survival (PFS) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation

Intervention	Percentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006)	52.7
Placebo	54.8

PFS=time from randomization to first observed disease progression (radiological according to central assessment or clinical due to bone irradiation, whichever is earlier), or death due to any cause, if death occurred before progression. Progression was assessed by RECIST criteria, version 1.0, modified for bone lesions. PFS for participants without disease progression or death at the time of analysis or unblinding were censored at the last date of tumor assessment before unblinding. Participants with no tumor evaluation after baseline were censored at Day 1. PD (Progression Disease)=At least a 20% increase in sum of longest diameters (LD) of measured lesions taking as reference the smallest sum LD on study since the treatment started or the appearance of 1 or more new lesions. New lesions also constituted PD. In exceptional circumstances, unequivocal progression of a nonmeasured lesion may have been accepted as evidence of disease progression in participants with measurable disease. (NCT00984282)
Timeframe: Final analysis to be performed when approximately 267 progression-free survival events (centrally assessed) had occurred, study duration approximately three years

Response Rate Based on Central Assessment

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	329
Placebo	175

Response rate was defined as the proportion of subjects whose best response was CR or PR. Per RECIST, CR and PR was to be confirmed by another scan at least 4 weeks later. CR = Disappearance of all clinical and radiological evidence of tumor (both target and no-target). PR = At least a 30% decrease in the sum of LD of target lesions taking as reference the baseline sum. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Time to Progression (TTP) Based on Central Assessment Incl. Clinical Progression Due to Bone Irradiation

Intervention	Percentage of participants (Number)
Sorafenib (Nexavar, BAY43-9006)	12.24
Placebo	0.5

Time to progression was defined at the time (days) from randomization to progression (based on central assessment [radiological and clinical progression due to bone irradiation]) (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Maximum Percent Reduction in Target Lesion Size Based on Central Assessment

Intervention	Days (Median)
Sorafenib (Nexavar, BAY43-9006)	337
Placebo	175

The magnitude of change from baseline in target lesion size in evaluable participants with scans was determined. (NCT00984282)
Timeframe: From randomization of the first subject until the database cut-off (31 Aug 2012), study duration approximately three years

Number of Participants That Experienced Adverse Events to Characterize the Safety Profile of BAY 43-9006

Intervention	Percentage of participants (Number)
	Reduction ≥ 30%	Reduction ≥ 20% but < 30%	Reduction ≥ 10% but < 20%	Reduction > 0% but < 10%	Growth ≥ 0%	Not assessed
Placebo	1.0	1.5	3.5	21.9	62.7	9.5
Sorafenib (Nexavar, BAY43-9006)	17.3	15.3	22.4	22.4	12.8	9.7

The safety and toxicity profile of BAY 43-9006 as measured by toxicity grades of adverse events. (NCT00126568)
Timeframe: 27 months

Overall Survival Was Measured From the Date of Outset of Treatment to the Date of Death.

Progression Free Survival Was Measured From the Date of Outset of Treatment to the Date of Disease Progression.

Number of Patients With Response to Treatment Measured by RECIST Criteria

Intervention	Participants (Count of Participants)
Treatment (Sorafenib Tosylate)	20

Intervention	months (Median)
BAY 43-9006	3.9

Intervention	months (Median)
BAY 43-9006	1.9

Response evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. The patient's best response depends on the achievement of measurement and confirmation criteria of Complete Response (CR), Stable Disease (SD), Partial Response (PR) or Progressive Disease (PD). Measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded) as >20 mm with conventional techniques (CT, MRI, x-ray) or as >10 mm with spiral CT scan. (NCT00126568)
Timeframe: at 6 months after treatment

Article	Year
Which patient with thyroid cancer deserves systemic therapy and when? Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3 Topics: Antineoplastic Agents; Humans; Iodine Radioisotopes; Niacinamide; Patient Selection; Phenylurea Comp	2017
Protein kinase inhibitors for the treatment of advanced and progressive radiorefractory thyroid tumors: From the clinical trials to the real life. Best practice & research. Clinical endocrinology & metabolism, 2017, Volume: 31, Issue:3 Topics: Antineoplastic Agents; Chemotherapy, Adjuvant; Clinical Trials as Topic; Humans; Iodine Radioisotope	2017
Tyrosine kinase inhibitors rechallenge in solid tumors: a review of literature and a case description with lenvatinib in thyroid cancer. Expert review of anticancer therapy, 2017, Volume: 17, Issue:12 Topics: Adult; Antineoplastic Agents; Disease Progression; Female; Humans; Niacinamide; Phenylurea Compounds	2017
Sorafenib and thyroid cancer. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013, Volume: 27, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Carcinoma; Carcinoma, Neuroendocrine; Carci	2013
Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocrine-related cancer, 2014, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Iodine Radioisotopes; Niacinamide; Phenylu	2014
[Targeted therapies, prognostic and predictive factors in endocrine oncology]. Annales d'endocrinologie, 2013, Volume: 74 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Neuroendocrine; Clinical Trials, Phase III as Topic; Disease-Free	2013
Sorafenib in metastatic thyroid cancer: a systematic review. The oncologist, 2014, Volume: 19, Issue:3 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Disease Progression; Female; Humans; Male	2014
Development of molecular targeted drugs for advanced thyroid cancer in Japan. Endocrine journal, 2014, Volume: 61, Issue:9 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Japan; Molecular Targeted Therapy; Neovascu	2014
Sorafenib (Nexavar) for thyroid cancer. The Medical letter on drugs and therapeutics, 2014, May-26, Volume: 56, Issue:1443 Topics: Animals; Antineoplastic Agents; Dermatitis, Exfoliative; Humans; Niacinamide; Phenylurea Compounds;	2014
The evolving field of kinase inhibitors in thyroid cancer. Critical reviews in oncology/hematology, 2015, Volume: 93, Issue:1 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds;	2015
Sorafenib for the treatment of thyroid cancer: an updated review. Expert opinion on pharmacotherapy, 2015, Volume: 16, Issue:4 Topics: Antineoplastic Agents; Disease-Free Survival; Humans; Iodine Radioisotopes; Niacinamide; Phenylurea	2015
Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. The oncologist, 2015, Volume: 20, Issue:2 Topics: Disease-Free Survival; Humans; Indoles; Iodine Radioisotopes; MAP Kinase Kinase Kinase 1; Niacinamid	2015
The discovery and development of sorafenib for the treatment of thyroid cancer. Expert opinion on drug discovery, 2015, Volume: 10, Issue:4 Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Drug Approval; Drug Design; Humans; Molecular	2015
Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma. Targeted oncology, 2015, Volume: 10, Issue:1 Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid Neoplasms	2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond. Anti-cancer drugs, 2015, Volume: 26, Issue:7 Topics: Antineoplastic Agents; Clinical Trials, Phase II as Topic; Humans; Iodine Radioisotopes; Mutation; N	2015
Targeted therapies in advanced differentiated thyroid cancer. Cancer treatment reviews, 2015, Volume: 41, Issue:8 Topics: Antineoplastic Agents; Humans; Molecular Targeted Therapy; Neoplasm Staging; Niacinamide; Outcome As	2015
Aggressive thyroid cancer: targeted therapy with sorafenib. Minerva endocrinologica, 2017, Volume: 42, Issue:1 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Humans; Neoplasm Metastasis; Niacinamide; Phenylurea	2017
Sorafenib: 10 years after the first pivotal trial. Future oncology (London, England), 2015, Volume: 11, Issue:13 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Liver Neoplasms; Ni	2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies. Targeted oncology, 2015, Volume: 10, Issue:3 Topics: Anilides; Antineoplastic Agents; Axitinib; Carcinoma, Neuroendocrine; DNA Mutational Analysis; Drug	2015
Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature. Journal of cancer research and therapeutics, 2015, Volume: 11 Suppl 2 Topics: Antineoplastic Agents; Female; Humans; Male; Neoplasm Recurrence, Local; Niacinamide; Odds Ratio; Ph	2015
Targeted treatments of radio-iodine refractory differentiated thyroid cancer. Annales d'endocrinologie, 2015, Volume: 76, Issue:1 Suppl 1 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Iodine Radioisotopes; Niacinamide; Phenylur	2015
Toxic Effects of Sorafenib in Patients With Differentiated Thyroid Carcinoma Compared With Other Cancers. JAMA oncology, 2016, Volume: 2, Issue:4 Topics: Antineoplastic Agents; Carcinoma; Humans; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; T	2016
[New molecular target therapy for thyroid neoplasms and malignant melanomas]. Nihon Jibiinkoka Gakkai kaiho, 2015, Volume: 118, Issue:11 Topics: Antibodies, Monoclonal; Antineoplastic Agents; Clinical Trials as Topic; Humans; Indoles; Ipilimumab	2015
Selective use of sorafenib in the treatment of thyroid cancer. Drug design, development and therapy, 2016, Volume: 10 Topics: Antineoplastic Agents; Cell Proliferation; Humans; Niacinamide; Phenylurea Compounds; Sorafenib; Thy	2016
Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib. Expert review of anticancer therapy, 2016, Volume: 16, Issue:12 Topics: Antineoplastic Agents; Humans; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Protein Kinase I	2016
Neoadjuvant Therapy in Differentiated Thyroid Cancer. International journal of surgical oncology, 2016, Volume: 2016 Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; Clinical Trials as Topic; Doxoru	2016
Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E). Biochimica et biophysica acta, 2009, Volume: 1795, Issue:2 Topics: Benzenesulfonates; Biopsy, Needle; Humans; Isoquinolines; Mutation; Niacinamide; Phenylurea Compound	2009
Tyrosine kinase inhibitors and the thyroid. Best practice & research. Clinical endocrinology & metabolism, 2009, Volume: 23, Issue:6 Topics: Axitinib; Benzenesulfonates; Clinical Trials as Topic; Gefitinib; Humans; Imidazoles; Indazoles; Ind	2009
Targeting vascular endothelial growth factor receptor in thyroid cancer: the intracellular and extracellular implications. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Feb-01, Volume: 16, Issue:3 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Benzenesulfonates; Drug Delivery Systems; Humans; MA	2010
Targeted molecular therapies in thyroid carcinoma. Arquivos brasileiros de endocrinologia e metabologia, 2009, Volume: 53, Issue:9 Topics: Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Huma	2009
Sorafenib: rays of hope in thyroid cancer. Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interact	2010
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer. Endocrine journal, 2011, Volume: 58, Issue:3 Topics: Anilides; Benzenesulfonates; Disease Progression; Humans; Molecular Targeted Therapy; Niacinamide; P	2011
Novel molecular targeted therapies for refractory thyroid cancer. Head & neck, 2012, Volume: 34, Issue:5 Topics: Angiogenesis Inhibitors; Anilides; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; B	2012
Role of BRAF in thyroid oncogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Dec-15, Volume: 17, Issue:24 Topics: Benzenesulfonates; Cell Transformation, Neoplastic; Genetic Predisposition to Disease; Humans; Mutat	2011
Hypothyroidism during treatment with tyrosine kinase inhibitors. Endokrynologia Polska, 2012, Volume: 63, Issue:4 Topics: Carcinoma, Renal Cell; Dose-Response Relationship, Drug; Gastrointestinal Neoplasms; Humans; Indoles	2012
How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. The Journal of endocrinology, 2004, Volume: 183, Issue:2 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Carcinoma, Papillary; Human	2004
Early clinical studies of novel therapies for thyroid cancers. Endocrinology and metabolism clinics of North America, 2008, Volume: 37, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Axitinib; Benzamides; Benzenesulfonates; Carcinoma;	2008

Article	Year
Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma. Thyroid : official journal of the American Thyroid Association, 2017, Volume: 27, Issue:9 Topics: Adult; Alopecia; Antineoplastic Agents; Carcinoma, Neuroendocrine; Diarrhea; Drug Resistance, Neopla	2017
Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer. Cancer, 2017, Nov-01, Volume: 123, Issue:21 Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Co	2017
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adult; Aged; Aged, 80 and over; Anilides; Antineoplastic Agents; Biomarkers, Tumor; Calcitonin; Carc	2013
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer. The oncologist, 2013, Volume: 18, Issue:12 Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Neuroendocrine; Disease-Free Surviv	2013
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-M	2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-M	2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-M	2014
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Double-Blind Method; Female; Humans; Kaplan-M	2014
Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocrine-related cancer, 2015, Volume: 22, Issue:6 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Antineoplastic Agents; Carcinoma, Papillary; D	2015
Phase II trial of sorafenib in advanced thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Midd	2008
Phase II trial of sorafenib in advanced thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Midd	2008
Phase II trial of sorafenib in advanced thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Midd	2008
Phase II trial of sorafenib in advanced thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2008, Oct-10, Volume: 26, Issue:29 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Male; Midd	2008
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Jul-03, Volume: 359, Issue:1 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent	2008
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Jul-03, Volume: 359, Issue:1 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent	2008
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Jul-03, Volume: 359, Issue:1 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent	2008
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Jul-03, Volume: 359, Issue:1 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Aged, 80 and over; Antineoplastic Agent	2008
Phase II trial of sorafenib in metastatic thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Apr-01, Volume: 27, Issue:10 Topics: Adenocarcinoma, Papillary; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates;	2009
Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Aug-10, Volume: 27, Issue:23 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Medullary; Female; Humans; Indoles; Male; Middle Aged	2009
Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. European journal of endocrinology, 2009, Volume: 161, Issue:6 Topics: Adenocarcinoma, Follicular; Aged; Aged, 80 and over; Benzenesulfonates; Bone Neoplasms; Disease-Free	2009
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, May-10, Volume: 28, Issue:14 Topics: Administration, Oral; Adult; Aged; Benzenesulfonates; Biomarkers, Tumor; Carcinoma, Medullary; Disea	2010
Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:8 Topics: Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma; Female; Humans; Hypothyroidism; Male; Middle	2010
Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:11 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Carcinoma, Medullary;	2010
Sorafenib: rays of hope in thyroid cancer. Thyroid : official journal of the American Thyroid Association, 2010, Volume: 20, Issue:12 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Disease-Free Survival; Drug Interact	2010
Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; China; Disea	2011
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:4 Topics: Adenocarcinoma, Follicular; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Pro	2011
In vitro transforming potential, intracellular signaling properties, and sensitivity to a kinase inhibitor (sorafenib) of RET proto-oncogene variants Glu511Lys, Ser649Leu, and Arg886Trp. Endocrine-related cancer, 2011, Volume: 18, Issue:4 Topics: Adult; Aged; Animals; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Benzenesulfonates	2011
Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. European journal of endocrinology, 2011, Volume: 165, Issue:2 Topics: Adult; Aged; Antineoplastic Agents; Benzenesulfonates; Carcinoma; Female; Humans; Male; Middle Aged;	2011
Rationale and design of decision: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid ca BMC cancer, 2011, Aug-11, Volume: 11 Topics: Antineoplastic Agents; Benzenesulfonates; Clinical Protocols; Double-Blind Method; Drug Administrati	2011
Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trial. European journal of endocrinology, 2012, Volume: 167, Issue:5 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Aged; Aged, 80 and over; Antineoplastic Agents; Benz	2012
Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid : official journal of the American Thyroid Association, 2013, Volume: 23, Issue:5 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Drug Eruptions; Drug Resistance, Multiple; Drug Resis	2013

Article	Year
Valuable insights from real-life experiences of advanced thyroid cancer treatment with sorafenib in Latin America. Archives of endocrinology and metabolism, 2021, 09-02, Volume: 65, Issue:4 Topics: Antineoplastic Agents; Humans; Latin America; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid	2021
Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment. Cancer chemotherapy and pharmacology, 2022, Volume: 89, Issue:6 Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Carcinoma, Renal Cell; Humans; Kidney; Kidney Neop	2022
Quercetin improves the effects of sorafenib on growth and migration of thyroid cancer cells. Endocrine, 2020, Volume: 67, Issue:2 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Humans; Niacinamide; Phenylurea Compoun	2020
Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT. Clinical nuclear medicine, 2020, Volume: 45, Issue:3 Topics: Adenoma, Oxyphilic; Aged; Biological Transport; Fluorine Radioisotopes; Humans; Male; Neoplasm Stagi	2020
Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer. Thyroid : official journal of the American Thyroid Association, 2017, Volume: 27, Issue:8 Topics: Aged; Antineoplastic Agents; Cell Differentiation; Clinical Trials, Phase III as Topic; Controlled C	2017
Inhibition of the AKT/mTOR Pathway Augments the Anticancer Effects of Sorafenib in Thyroid Cancer. Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:5 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Humans; Niacinam	2017
Effects of sorafenib and an adenylyl cyclase activator on in vitro growth of well-differentiated thyroid cancer cells. Endocrine journal, 2017, Nov-29, Volume: 64, Issue:11 Topics: Adenylyl Cyclases; Cell Differentiation; Cell Proliferation; Colforsin; Cyclic AMP; Humans; MAP Kina	2017
Inhibition of autophagy enhances the targeted therapeutic effect of sorafenib in thyroid cancer. Oncology reports, 2018, Volume: 39, Issue:2 Topics: Animals; Antineoplastic Agents; Autophagy; Autophagy-Related Protein 5; Cell Line, Tumor; Chloroquin	2018
Tyrosine kinase inhibitors in iodine-refractory differentiated thyroid cancer: experience in clinical practice. Endocrine, 2018, Volume: 59, Issue:2 Topics: Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents; Axitinib; Carcin	2018
Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer. Archives of endocrinology and metabolism, 2018, Volume: 62, Issue:3 Topics: Antineoplastic Agents; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Male; Neoadjuvant Therapy	2018
Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:1 Topics: Carcinoma; Carcinoma, Papillary; Child; Humans; Hypoxia; Iodine Radioisotopes; Lung Neoplasms; Male;	2014
Metabolic response demonstrated by 18F-FDG-PET/CT in metastatic medullary thyroid carcinoma under sorafenib therapy. Endocrine, 2013, Volume: 44, Issue:1 Topics: Antineoplastic Agents; Biomarkers, Pharmacological; Biomarkers, Tumor; Carcinoma, Neuroendocrine; Fe	2013
Unilateral renal artery stenosis with renal atrophy in a patient with metastatic papillary thyroid carcinoma treated with sorafenib. BMJ case reports, 2013, May-15, Volume: 2013 Topics: Antineoplastic Agents; Atrophy; Carcinoma; Carcinoma, Papillary; Female; Humans; Kidney; Middle Aged	2013
Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report. Onkologie, 2013, Volume: 36, Issue:6 Topics: Adenocarcinoma, Follicular; Adult; Boronic Acids; Bortezomib; Female; Humans; Kidney Neoplasms; Lung	2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer. The Journal of surgical research, 2013, Volume: 185, Issue:2 Topics: Animals; Apoptosis; Benzazepines; Cell Proliferation; Drug Evaluation, Preclinical; Humans; Male; Mi	2013
Sorafenib makes headway on metastatic thyroid cancer. Cancer discovery, 2013, Volume: 3, Issue:7 Topics: Humans; Neoplasm Metastasis; Niacinamide; Phenylurea Compounds; Randomized Controlled Trials as Topi	2013
Critical role of sorafenib exposure over time for its antitumor activity in thyroid cancer. Investigational new drugs, 2014, Volume: 32, Issue:3 Topics: Aged; Antineoplastic Agents; Female; Humans; Lung Neoplasms; Niacinamide; Phenylurea Compounds; Prot	2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. European journal of endocrinology, 2014, Volume: 170, Issue:4 Topics: Adenocarcinoma; Adenocarcinoma, Follicular; Adenoma, Oxyphilic; Adult; Aged; Antineoplastic Agents;	2014
Complete resolution of hypercortisolism with sorafenib in a patient with advanced medullary thyroid carcinoma and ectopic ACTH (adrenocorticotropic hormone) syndrome. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:6 Topics: ACTH Syndrome, Ectopic; Carcinoma, Neuroendocrine; Humans; Male; Middle Aged; Niacinamide; Phenylure	2014
Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. The Journal of clinical endocrinology and metabolism, 2014, Volume: 99, Issue:6 Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Papillary, Follicular; Chemo	2014
More effective agents still needed for progressive radioiodine-refractory differentiated thyroid cancer. Endocrine-related cancer, 2014, Volume: 21, Issue:2 Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafen	2014
Notable decrease of malignant pleural effusion after treatment with sorafenib in radioiodine-refractory follicular thyroid carcinoma. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:7 Topics: Adenocarcinoma, Follicular; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phen	2014
Response to sorafenib treatment in advanced metastatic thyroid cancer. Arquivos brasileiros de endocrinologia e metabologia, 2014, Volume: 58, Issue:1 Topics: Aged; Antineoplastic Agents; Bone Neoplasms; Carcinoma, Papillary; Compassionate Use Trials; Female;	2014
Efficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancer. The oncologist, 2014, Volume: 19, Issue:5 Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Carcinoma; Carcinoma, Papillary; Disease Progression; Dis	2014
New era for treatment in differentiated thyroid cancer. Lancet (London, England), 2014, Jul-26, Volume: 384, Issue:9940 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Sorafenib; Thyroid N	2014
(99m)Tc-labeled-rhTSH analogue (TR1401) for imaging poorly differentiated metastatic thyroid cancer. Thyroid : official journal of the American Thyroid Association, 2014, Volume: 24, Issue:8 Topics: Animals; Cattle; Cell Differentiation; Cell Separation; CHO Cells; Cricetinae; Cricetulus; Dogs; Flo	2014
In reply. The oncologist, 2014, Volume: 19, Issue:8 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Thyroid Neoplasms	2014
Sorafenib in thyroid cancer patients: learning from toxicity. The oncologist, 2014, Volume: 19, Issue:8 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Thyroid Neoplasms	2014
Efficacy of sorafenib and impact on cardiac function in patients with thyroid cancer: a retrospective analysis. Journal of endocrinological investigation, 2014, Volume: 37, Issue:11 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Electrocardiography; Female; Foll	2014
Second-line sunitinib as a feasible approach for iodine-refractory differentiated thyroid cancer after the failure of first-line sorafenib. Endocrine, 2015, Volume: 49, Issue:3 Topics: Antineoplastic Agents; Disease Progression; Drug Resistance, Neoplasm; Female; Humans; Indoles; Iodi	2015
To treat or not to treat: developments in the field of advanced differentiated thyroid cancer. The Netherlands journal of medicine, 2014, Volume: 72, Issue:8 Topics: Adenocarcinoma, Follicular; Aged; Clinical Trials, Phase I as Topic; Drug Delivery Systems; Female;	2014
Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single center. Endocrine, 2015, Volume: 49, Issue:3 Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Disease-F	2015
[Treatment of patients with radioiodine refractory, differentiated thyroid carcinoma. A Consensus Statement]. Nuklearmedizin. Nuclear medicine, 2015, Volume: 54, Issue:3 Topics: Antineoplastic Agents; Chemoradiotherapy; Evidence-Based Medicine; Germany; Humans; Iodine Radioisot	2015
Thyroid carcinoma, version 2.2014. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:12 Topics: Adenocarcinoma; Anilides; Carcinoma, Neuroendocrine; Guidelines as Topic; Humans; Neoplasm Metastasi	2014
The proteomic 2D-DIGE approach reveals the protein voltage-dependent anion channel 2 as a potential therapeutic target in epithelial thyroid tumours. Molecular and cellular endocrinology, 2015, Mar-15, Volume: 404 Topics: Adolescent; Adult; Aged; Aged, 80 and over; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associ	2015
Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncology reports, 2015, Volume: 33, Issue:4 Topics: Antineoplastic Agents; Apoptosis; Carcinoma; Cell Cycle Checkpoints; Cell Line, Tumor; Dose-Response	2015
Sorafenib for patients with differentiated thyroid cancer. Lancet (London, England), 2015, Jan-17, Volume: 385, Issue:9964 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Thyroid Neoplasms	2015
Sorafenib for patients with differentiated thyroid cancer. Lancet (London, England), 2015, Jan-17, Volume: 385, Issue:9964 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Thyroid Neoplasms	2015
Sorafenib for patients with differentiated thyroid cancer--authors' reply. Lancet (London, England), 2015, Jan-17, Volume: 385, Issue:9964 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Thyroid Neoplasms	2015
Sorafenib for patients with differentiated thyroid cancer. Lancet (London, England), 2015, Jan-17, Volume: 385, Issue:9964 Topics: Antineoplastic Agents; Female; Humans; Male; Niacinamide; Phenylurea Compounds; Thyroid Neoplasms	2015
Complete disappearance of liver metastases in a patient with iodine-refractory differentiated thyroid cancer subjected to sorafenib re-challenge. Endocrine, 2015, Volume: 50, Issue:3 Topics: Antineoplastic Agents; Female; Humans; Iodine Radioisotopes; Liver; Liver Neoplasms; Middle Aged; Ni	2015
Iodide- and glucose-handling gene expression regulated by sorafenib or cabozantinib in papillary thyroid cancer. The Journal of clinical endocrinology and metabolism, 2015, Volume: 100, Issue:5 Topics: Anilides; Antineoplastic Agents; Apoptosis; Autoantigens; Carcinoma, Papillary; Cell Cycle; Cell Lin	2015
Sorafenib inhibits intracellular signaling pathways and induces cell cycle arrest and cell death in thyroid carcinoma cells irrespective of histological origin or BRAF mutational status. BMC cancer, 2015, Mar-26, Volume: 15 Topics: Antineoplastic Agents; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Survival; Humans;	2015
Effects of Cancer Therapy Targeting Vascular Endothelial Growth Factor Receptor on Central Blood Pressure and Cardiovascular System. American journal of hypertension, 2016, Volume: 29, Issue:2 Topics: Aged; Antineoplastic Agents; Arteries; Blood Pressure; Carcinoma, Renal Cell; Female; Heart; Humans;	2016
Sorafenib in the treatment of thyroid cancer. Expert review of anticancer therapy, 2015, Volume: 15, Issue:8 Topics: Animals; Antineoplastic Agents; Disease-Free Survival; Humans; Neoplasm Metastasis; Niacinamide; Phe	2015
The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells. Journal of immunology (Baltimore, Md. : 1950), 2015, Sep-01, Volume: 195, Issue:5 Topics: Animals; Cell Line, Tumor; Cells, Cultured; Dose-Response Relationship, Drug; Flow Cytometry; Gene E	2015
[Molecular targeting treatment for thyroid cancer]. Gan to kagaku ryoho. Cancer & chemotherapy, 2015, Volume: 42, Issue:7 Topics: Antineoplastic Agents; Clinical Trials as Topic; Humans; Molecular Targeted Therapy; Niacinamide; Ph	2015
Combinatorial anticancer effects of curcumin and sorafenib towards thyroid cancer cells via PI3K/Akt and ERK pathways. Natural product research, 2016, Volume: 30, Issue:16 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Line, Tumor; Cell Movement; Curcumin	2016
Partial response to sorafenib treatment associated with transient grade 3 thrombocytopenia in a patient with locally advanced thyroid cancer. Archives of endocrinology and metabolism, 2015, Volume: 59, Issue:4 Topics: Aged; Antineoplastic Agents; Female; Humans; Neoplasm Recurrence, Local; Neoplasm Staging; Niacinami	2015
Case report of severe Cushing's syndrome in medullary thyroid cancer complicated by functional diabetes insipidus, aortic dissection, jejunal intussusception, and paraneoplastic dysautonomia: remission with sorafenib without reduction in cortisol concentr BMC cancer, 2015, Sep-09, Volume: 15 Topics: Adult; Antineoplastic Agents; Aortic Aneurysm; Aortic Dissection; Carcinoma, Medullary; Cushing Synd	2015
Targeted therapy for advanced or metastatic differentiated thyroid carcinoma. Clinical advances in hematology & oncology : H&O, 2015, Volume: 13, Issue:4 Suppl 4 Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Humans; Molecular Targeted Therapy; Neoplasm Recur	2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma. Asian Pacific journal of cancer prevention : APJCP, 2015, Volume: 16, Issue:16 Topics: Angiogenesis Inhibitors; Anilides; Carcinoma, Neuroendocrine; Databases, Chemical; Drug Discovery; H	2015
Sorafenib for the Treatment of Progressive Metastatic Medullary Thyroid Cancer: Efficacy and Safety Analysis. Thyroid : official journal of the American Thyroid Association, 2016, Volume: 26, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Neuroendocrine; Disease Progression; Disease-Free Sur	2016
B-Raf Inhibition in the Clinic: Present and Future. Annual review of medicine, 2016, Volume: 67 Topics: Antineoplastic Agents; Colonic Neoplasms; Drug Resistance, Neoplasm; Humans; Imidazoles; Indoles; MA	2016
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges. BMC cancer, 2016, Jan-19, Volume: 16 Topics: Aged; Apoptosis; Carcinogenesis; Carcinoma, Squamous Cell; Female; Humans; Male; Middle Aged; Mutati	2016
pAKT Expression and Response to Sorafenib in Differentiated Thyroid Cancer. Hormones & cancer, 2016, Volume: 7, Issue:3 Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Endothelial Cells; Female; Gene Expression; Humans;	2016
Sorafenib (NEXAVAR) and differentiated thyroid cancer. Toxic, and no proof of improved survival. Prescrire international, 2016, Volume: 25, Issue:168 Topics: Antineoplastic Agents; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafen	2016
Effects of the multikinase inhibitors Sorafenib and Regorafenib in PTEN deficient neoplasias. European journal of cancer (Oxford, England : 1990), 2016, Volume: 63 Topics: Animals; Antineoplastic Agents; Carcinoma; Cell Line, Tumor; Disease Models, Animal; Endometrial Neo	2016
Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC). Clinical cancer research : an official journal of the American Association for Cancer Research, 2016, Dec-15, Volume: 22, Issue:24 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Biomarkers, Tumor; Cell Li	2016
Efficacy of lenvatinib in treating thyroid cancer. Expert opinion on pharmacotherapy, 2016, Volume: 17, Issue:12 Topics: Biomarkers; Calcitonin; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Half-Life; Humans; Niac	2016
68Ga DOTATATE PET/CT in Differentiated Thyroid Carcinoma With Fibular Metastasis and Mixed Response to Sorafenib. Clinical nuclear medicine, 2016, Volume: 41, Issue:10 Topics: Female; Humans; Middle Aged; Neoplasm Metastasis; Niacinamide; Organometallic Compounds; Phenylurea	2016
[Lenvatinib in radioiodine refractory thyroid carcinomas]. Bulletin du cancer, 2016, Volume: 103, Issue:11 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Clinical Trials as Topic; Compassionate Use Trial	2016
Timing of multikinase inhibitor initiation in differentiated thyroid cancer. Endocrine-related cancer, 2017, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Administration Schedule; Fema	2017
Targeted therapeutic approach for an anaplastic thyroid cancer in vitro and in vivo. Cancer science, 2008, Volume: 99, Issue:9 Topics: Antineoplastic Agents; Benzenesulfonates; Boronic Acids; Bortezomib; Carcinoma; Cell Line, Tumor; Hu	2008
Sorafenib potently inhibits papillary thyroid carcinomas harboring RET/PTC1 rearrangement. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Aug-01, Volume: 14, Issue:15 Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Cell Line, Tumor; Cell Prol	2008
Sorafenib-induced liver failure. The American journal of gastroenterology, 2008, Volume: 103, Issue:8 Topics: Adenocarcinoma, Follicular; Aged; Antineoplastic Agents; Benzenesulfonates; Female; Humans; Liver Fa	2008
Motesanib diphosphate in progressive differentiated thyroid cancer. The New England journal of medicine, 2008, Dec-18, Volume: 359, Issue:25 Topics: Adenocarcinoma, Follicular; Biomarkers, Tumor; Disease Progression; Humans; Indoles; Mitogen-Activat	2008
The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid : official journal of the American Thyroid Association, 2009, Volume: 19, Issue:4 Topics: Adolescent; Benzenesulfonates; Carcinoma, Papillary; Child; Female; Humans; Iodine Radioisotopes; Lu	2009
Sorafenib induces partial response in metastatic medullary thyroid carcinoma. Acta oncologica (Stockholm, Sweden), 2010, Volume: 49, Issue:1 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Bone Neoplasms; Carcinoma, Neuroendocrine; Humans;	2010
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC cancer, 2009, Oct-31, Volume: 9 Topics: Apoptosis; Apoptosis Regulatory Proteins; Benzenesulfonates; Cell Line, Tumor; Cell Proliferation; C	2009
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinoma. Molecular cancer therapeutics, 2010, Volume: 9, Issue:1 Topics: Animals; Antigens, Bacterial; Bacterial Toxins; Benzenesulfonates; Carcinoma; Cell Line, Tumor; Cell	2010
Sorafenib-induced psoriasiform eruption in a patient with metastatic thyroid carcinoma. Journal of drugs in dermatology : JDD, 2010, Volume: 9, Issue:2 Topics: Antineoplastic Agents; Benzenesulfonates; Drug Eruptions; Humans; Male; Middle Aged; Neoplasm Metast	2010
Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzenesulfonates; Disease Progression; Disea	2010
Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. The Journal of clinical endocrinology and metabolism, 2010, Volume: 95, Issue:6 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Biomarkers, Tumor; Carcinoma,	2010
Parenchymal versus nonparenchymal target lesion response in clinical trials for metastatic medullary thyroid cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Oct-01, Volume: 28, Issue:28 Topics: Administration, Oral; Benzenesulfonates; Biomarkers, Tumor; Calcitonin; Carcinoembryonic Antigen; Ca	2010
Rapid response to sorafenib in metastatic medullary thyroid carcinoma. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2011, Volume: 119, Issue:3 Topics: Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Carcinoma, Neuroendo	2011
Population pharmacokinetic/pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Carcinoma, Medullary; Drug Administration Sche	2010
Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer. Cancer chemotherapy and pharmacology, 2010, Volume: 66, Issue:6 Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Disease-Free Survival; Dose-Response Relations	2010
Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:1 Topics: Animals; Apoptosis; Benzenesulfonates; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cell	2011
Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid : official journal of the American Thyroid Association, 2011, Volume: 21, Issue:4 Topics: Acute Coronary Syndrome; Benzamides; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Fatal Outco	2011
Anti-tumor activity of motesanib in a medullary thyroid cancer model. Journal of endocrinological investigation, 2012, Volume: 35, Issue:2 Topics: Animals; Antineoplastic Agents; Carcinoma, Neuroendocrine; Cell Line, Tumor; Cells, Cultured; Female	2012
A painful cranial bulge. Lancet (London, England), 2011, May-21, Volume: 377, Issue:9779 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Drug Administ	2011
Laryngeal metastasis as first presentation of hepatocellular carcinoma. Revista espanola de enfermedades digestivas, 2011, Volume: 103, Issue:4 Topics: Adenoma, Oxyphilic; Antineoplastic Agents; Biopsy, Fine-Needle; Carcinoma, Hepatocellular; Combined	2011
[New therapeutic options for advanced thyroid cancer]. Deutsche medizinische Wochenschrift (1946), 2011, Volume: 136, Issue:22 Topics: Antineoplastic Agents; Benzenesulfonates; Humans; Indoles; Niacinamide; Phenylurea Compounds; Piperi	2011
Transient partial response to sorafenib treatment in an adolescent patient with MEN2B syndrome and end-stage medullary thyroid carcinoma. Pediatric blood & cancer, 2012, Volume: 58, Issue:1 Topics: Adolescent; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Female; Humans; Multiple	2012
The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. The Journal of clinical endocrinology and metabolism, 2011, Volume: 96, Issue:10 Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Papillary; Humans; Iodine Radioisotopes; Neopla	2011
[Long-standing differentiated thyroid carcinoma]. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2012, Volume: 59, Issue:1 Topics: Antineoplastic Agents; Benzenesulfonates; Biopsy, Needle; Carcinoma, Large Cell; Carcinoma, Papillar	2012
Sorafenib and Mek inhibition is synergistic in medullary thyroid carcinoma in vitro. Endocrine-related cancer, 2012, Volume: 19, Issue:1 Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Benzimidaz	2012
Sorafenib in metastatic thyroid cancer. Endocrine-related cancer, 2012, Volume: 19, Issue:2 Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Calcitonin; Carcinoembryonic Antigen; Disease-Free	2012
[Endocrinology]. Revue medicale suisse, 2012, Jan-11, Volume: 8, Issue:323 Topics: ACTH-Secreting Pituitary Adenoma; Adenoma; Benzenesulfonates; Carcinoma; Carcinoma, Medullary; Clini	2012
Pancreatic metastasis arising from a BRAF(V600E)-positive papillary thyroid cancer: the role of endoscopic ultrasound-guided biopsy and response to sorafenib therapy. Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:5 Topics: Benzenesulfonates; Biopsy; Carcinoma; Carcinoma, Papillary; Disease Progression; Endoscopy; Fatal Ou	2012
Therapeutic management of metastatic medullary thyroid carcinoma: role of new tyrosine kinase inhibitors. Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion, 2013, Volume: 60, Issue:3 Topics: Carcinoma, Neuroendocrine; Humans; Lymphatic Metastasis; Male; Middle Aged; Niacinamide; Phenylurea	2013
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma. The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:9 Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy	2012
Functional characterization of the novel BRAF complex mutation, BRAF(V600delinsYM) , identified in papillary thyroid carcinoma. International journal of cancer, 2013, Feb-01, Volume: 132, Issue:3 Topics: 3T3 Cells; Amino Acid Substitution; Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cel	2013
Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. Thyroid : official journal of the American Thyroid Association, 2012, Volume: 22, Issue:8 Topics: Adenocarcinoma, Follicular; Antineoplastic Agents; Benzenesulfonates; Brain Neoplasms; Female; Human	2012
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. Clinical endocrinology, 2013, Volume: 78, Issue:5 Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Niacinamide; Pheny	2013
Sorafenib therapy decreases the clearance of thyrotropin. European journal of endocrinology, 2013, Volume: 168, Issue:2 Topics: Aged; Aged, 80 and over; Carcinoma; Dose-Response Relationship, Drug; Female; Humans; Male; Middle A	2013
Autophagic activation potentiates the antiproliferative effects of tyrosine kinase inhibitors in medullary thyroid cancer. Surgery, 2012, Volume: 152, Issue:6 Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Benzimidazoles; Carcinoma, Neuroendocrine; Cell	2012
A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers. American journal of surgery, 2012, Volume: 204, Issue:6 Topics: Antineoplastic Agents; Apoptosis; Benzenesulfonates; Blotting, Western; Carcinoma; Carcinoma, Papill	2012
[Effects of sorafenib and liposome doxorubicin on human poorly differentiated thyroid carcinoma xenografts in nude mice]. Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery, 2012, Volume: 47, Issue:11 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Humans; Liposomes; Mice; Mice,	2012
Nicotinamide increases thyroid radiosensitivity by stimulating nitric oxide synthase expression and the generation of organic peroxides. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2006, Volume: 38, Issue:1 Topics: Animals; Gene Expression Regulation, Enzymologic; Hyperthyroidism; Iodine Radioisotopes; Male; Niaci	2006
BAY 43-9006 inhibition of oncogenic RET mutants. Journal of the National Cancer Institute, 2006, Mar-01, Volume: 98, Issue:5 Topics: Administration, Oral; Animals; Antineoplastic Agents; Benzenesulfonates; Cell Cycle; Drug Administra	2006
BRAF is a therapeutic target in aggressive thyroid carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Mar-01, Volume: 12, Issue:5 Topics: Animals; Benzenesulfonates; Carcinoma; Carcinoma, Papillary; Cell Proliferation; Humans; Male; Mice;	2006
Sorafenib inhibits the angiogenesis and growth of orthotopic anaplastic thyroid carcinoma xenografts in nude mice. Molecular cancer therapeutics, 2007, Volume: 6, Issue:6 Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Benzenesulfonates; Cell Division; Humans; Immunohistoch	2007
Optimization of boron neutron capture therapy for the treatment of undifferentiated thyroid cancer. International journal of radiation oncology, biology, physics, 2007, Nov-15, Volume: 69, Issue:4 Topics: Animals; Apoptosis; Boron Compounds; Boron Neutron Capture Therapy; Cell Line, Tumor; Deuteroporphyr	2007
Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Molecular cancer therapeutics, 2008, Volume: 7, Issue:5 Topics: Adult; Amino Acid Sequence; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Medullary; Cell Lin	2008
Notes on streptozotocin in metastatic insulinoma. Journal of surgical oncology, 1971, Volume: 3, Issue:5 Topics: Adenoma, Islet Cell; Adult; Antibiotics, Antineoplastic; Autopsy; Blood Glucose; Bone Marrow; Brain;	1971

niacinamide and Thyroid Neoplasms